Santiago Villafaña-Hernandez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Santiago Villafaña-Hernandez has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Asdrubal Aguilera-Méndez
Instituto de Investigaciones Químico Biológicas, Universidad Michoacana de San Nicolás de Hidalgo, Morelia 58030, Mexico
1 shared publication - Elvia Mera Jiménez
Laboratorio de Cultivo Celular, Neurofarmacología y Conducta, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico
1 shared publication - Enrique Hong
Departamento de Neurofarmacobiología, Centro de Investigación y de Estudios Avanzados, Ciudad de México 14330, Mexico
1 shared publication - Martha Edith Macías Pérez
Laboratorio de Cultivo Celular, Neurofarmacología y Conducta, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico
1 shared publication - Rodrigo Romero-Nava
Laboratorio de Investigación en Genética de Enfermedades Metabólicas, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, Mexico City 11340, Mexico
1 shared publication - Rolando Alberto Rodríguez-Fonseca
Laboratorio de Cultivo Celular, Neurofarmacología y Conducta, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 94 (3) , 53
Development of a Rationally Designed siRNA-Based Therapeutic Targeting PD-L1 in Triple-Negative Breast Cancer
In triple-negative breast cancer (TNBC), immune checkpoint pathways play a central role in tumor immune evasion. Programmed death protein 1 (PD-1) is an inhibitory receptor expressed on T cells, while its ligand, programmed death-ligand 1 (PD-L1), is commonly expressed on tumor cells and cells within the tumor microenvironment. Their interaction suppresses T-cell activation and promotes immune escape. In this study, we evaluated the potential of small interfering RNA (siRNA) to silence PD-L1 expression in TNBC. Transcriptomic analysis of GEO datasets revealed consistent upregulation of CD274 (PD-L1) in TNBC samples. Three siRNA candidates were designed and evaluated in MDA-MB-231 cells. All siRNAs significantly reduced CD274 expression (>70%), as determined by RT-qPCR. Immunofluorescence analysis confirmed a reduction in PD-L1 protein levels (54.3 vs. 98.7 a.u.), while MTT assays demonstrated preserved cell viability at the working concentration (100 pM), supporting a non-cytotoxic and specific gene-silencing effect. These findings highlight PD-L1 as a viable molecular target and support siRNA-mediated silencing as a promising therapeutic strategy in TNBC.
- 30 June 2026
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 94 (3) , 53
Open AccessDevelopment of a Rationally Designed siRNA-Based Therapeutic Targeting PD-L1 in Triple-Negative Breast Cancer
In triple-negative breast cancer (TNBC), immune checkpoint pathways play a central role in tumor immune evasion. Programmed death protein 1 (PD-1) is an inhibitory receptor expressed on T cells, while its ligand, programmed death-ligand 1 (PD-L1), is commonly expressed on tumor cells and cells within the tumor microenvironment. Their interaction suppresses T-cell activation and promotes immune escape. In this study, we evaluated the potential of small interfering RNA (siRNA) to silence PD-L1 expression in TNBC. Transcriptomic analysis of GEO datasets revealed consistent upregulation of CD274 (PD-L1) in TNBC samples. Three siRNA candidates were designed and evaluated in MDA-MB-231 cells. All siRNAs significantly reduced CD274 expression (>70%), as determined by RT-qPCR. Immunofluorescence analysis confirmed a reduction in PD-L1 protein levels (54.3 vs. 98.7 a.u.), while MTT assays demonstrated preserved cell viability at the working concentration (100 pM), supporting a non-cytotoxic and specific gene-silencing effect. These findings highlight PD-L1 as a viable molecular target and support siRNA-mediated silencing as a promising therapeutic strategy in TNBC.